There is currently no simple, non-invasive or effective way of detecting or diagnosing lung cancers at an early stage. Often, diagnosis is made when the disease is already at an advanced stage, impacting on mortality. The team believe that signature biomarker expressions associated with the presence of lung cancer, are likely to be present in easily
accessible cells that do not require invasive approaches such as bronchoscopy. These changes in molecular markers could be leveraged to develop accurate lung cancer biomarkers for early detection and provide a means for routine diagnosis in at-risk patient populations. This pilot screening program will investigate the genetic differences between healthy and lung cancer patients to provide critical data to be used for a future wider cohort study and longer term epidemiological study of cancer disease progression.
Read full story here